STAAR Surgical (NASDAQ:STAA) Major Shareholder Broadwood Partners, L.P. Purchases 138,054 Shares

STAAR Surgical (NASDAQ:STAA) major shareholder Broadwood Partners, L.P. purchased 138,054 shares of the company’s stock in a transaction dated Monday, April 7th. The stock was purchased at an average price of $15.61 per share, for a total transaction of $2,155,022.94. Following the completion of the purchase, the insider now owns 13,332,264 shares in the company, valued at approximately $208,116,641.04. The trade was a 1.05 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Friday, April 4th, Broadwood Partners, L.P. bought 497,631 shares of STAAR Surgical stock. The stock was purchased at an average cost of $15.91 per share, for a total transaction of $7,917,309.21.
• On Wednesday, April 2nd, Broadwood Partners, L.P. purchased 31,780 shares of STAAR Surgical stock. The shares were purchased at an average price of $17.43 per share, with a total value of $553,925.40.
• On Monday, March 31st, Broadwood Partners, L.P. acquired 22,189 shares of STAAR Surgical stock. The stock was acquired at an average price of $17.46 per share, for a total transaction of $387,419.94.
• On Thursday, March 27th, Broadwood Partners, L.P. bought 3,620 shares of STAAR Surgical stock. The shares were acquired at an average price of $17.48 per share, with a total value of $63,277.60.
• On Tuesday, March 25th, Broadwood Partners, L.P. purchased 34,296 shares of STAAR Surgical stock. The stock was acquired at an average price of $17.44 per share, for a total transaction of $598,122.24.
• On Thursday, March 20th, Broadwood Partners, L.P. acquired 108,720 shares of STAAR Surgical stock. The stock was bought at an average price of $17.96 per share, with a total value of $1,952,611.20.
• On Tuesday, March 18th, Broadwood Partners, L.P. bought 93,124 shares of STAAR Surgical stock. The shares were bought at an average price of $17.54 per share, for a total transaction of $1,633,394.96.
• On Monday, March 3rd, Broadwood Partners, L.P. acquired 249,503 shares of STAAR Surgical stock. The shares were bought at an average cost of $16.64 per share, for a total transaction of $4,151,729.92.
• On Thursday, February 27th, Broadwood Partners, L.P. bought 259,316 shares of STAAR Surgical stock. The shares were purchased at an average price of $17.05 per share, for a total transaction of $4,421,337.80.
• On Friday, February 14th, Broadwood Partners, L.P. purchased 36,532 shares of STAAR Surgical stock. The stock was purchased at an average price of $15.49 per share, with a total value of $565,880.68.

STAAR Surgical Stock Up 1.4 %

STAAR Surgical stock traded up $0.22 during mid-day trading on Monday, reaching $16.14. 1,526,031 shares of the company’s stock traded hands, compared to its average volume of 784,406. STAAR Surgical has a 12-month low of $13.50 and a 12-month high of $52.68. The stock has a 50 day moving average of $18.65 and a two-hundred day moving average of $24.55. The company has a market cap of $796.11 million, a price-to-earnings ratio of -39.37 and a beta of 0.75.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of STAAR Surgical by 3.9% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,123 shares of the medical instruments supplier’s stock valued at $683,000 after purchasing an additional 1,044 shares during the last quarter. Quarry LP purchased a new stake in STAAR Surgical during the 3rd quarter valued at $50,000. MetLife Investment Management LLC raised its holdings in STAAR Surgical by 6.3% during the 4th quarter. MetLife Investment Management LLC now owns 30,396 shares of the medical instruments supplier’s stock valued at $738,000 after buying an additional 1,796 shares during the period. Bridgefront Capital LLC boosted its stake in STAAR Surgical by 27.2% during the fourth quarter. Bridgefront Capital LLC now owns 10,792 shares of the medical instruments supplier’s stock worth $262,000 after buying an additional 2,306 shares during the period. Finally, Illinois Municipal Retirement Fund raised its stake in shares of STAAR Surgical by 8.3% in the fourth quarter. Illinois Municipal Retirement Fund now owns 30,144 shares of the medical instruments supplier’s stock valued at $732,000 after acquiring an additional 2,318 shares during the period. Hedge funds and other institutional investors own 96.70% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently commented on STAA. Stephens restated an “equal weight” rating and set a $17.00 price objective on shares of STAAR Surgical in a research report on Tuesday, March 18th. Canaccord Genuity Group lowered their price objective on STAAR Surgical from $28.00 to $17.00 and set a “hold” rating on the stock in a research report on Thursday, February 13th. Needham & Company LLC reissued a “hold” rating on shares of STAAR Surgical in a report on Thursday, February 27th. BTIG Research cut shares of STAAR Surgical from a “buy” rating to a “neutral” rating in a research note on Wednesday, February 12th. Finally, StockNews.com cut shares of STAAR Surgical from a “hold” rating to a “sell” rating in a research note on Thursday, February 13th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat, STAAR Surgical currently has an average rating of “Hold” and a consensus price target of $25.29.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.